Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. - Through a network meta-analysis of placebo-controlled and head-to-head randomized controlled trials in 53,463 adults with acute symptoms of schizophrenia or related disorders, researchers contrasted and classified antipsychotics by quantifying information from randomized controlled trials. Effect size estimates recommended that all antipsychotics decreased overall symptoms more than placebo. Results for the primary outcome did not essentially alter following adjusting for possible influence moderators or in sensitivity analyses. The confidence in evidence was frequently low or very low. There were some efficiency variations between antipsychotics, although most of them were progressive rather than discrete. Variations in side effects were more significant. This would help clinicians in balancing the risks vs advantages of those drugs accessible in their countries. Moreover, they should acknowledge the significance of each outcome, the patients' medical problems, and preferences.